Related Experiment Video
Updated: Jul 8, 2026
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Antiplatelet therapy in management of transient ischemic attack: overview and evidence-based rationale
1Department of Neurology, University of California at Los Angeles, Los Angeles, California 90095, USA.
Insights
Transient ischemic attacks (TIAs) are common and carry a high risk of stroke. Timely antiplatelet therapy initiation is crucial for stroke prevention, yet many patients do not receive medication.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Public Health
Background:
- Transient ischemic attacks (TIAs) affect up to 300,000 individuals annually in the US, representing 0.3% of Emergency Department visits.
- TIAs are under-recognized and undertreated, posing a significant risk of subsequent stroke (up to 10% within 7 days) and mortality (25% at 1 year).
- Current treatment guidelines emphasize the importance of antiplatelet therapy in mitigating secondary stroke risk.
Purpose of the Study:
- To review recent findings from major antiplatelet clinical trials focused on stroke prevention.
- To emphasize the critical need for prompt and appropriate antiplatelet treatment initiation in TIA patients.
- To address the gap in medication prescription for TIA patients discharged from Emergency Departments.
Main Methods:
- Review of recent clinical trial data on antiplatelet agents in stroke prevention.
- Analysis of current treatment patterns for patients experiencing TIAs.
- Discussion of the implications of trial results for clinical practice.
Main Results:
- Antiplatelet therapy has demonstrated significant efficacy in reducing the risk of secondary strokes.
- A substantial proportion of TIA patients (nearly 50%) are discharged from Emergency Departments without prescribed antiplatelet medication.
- Recent clinical trials provide updated evidence supporting the benefits of specific antiplatelet regimens.
Conclusions:
- Timely initiation of antiplatelet therapy is a critical intervention for reducing secondary stroke risk after a TIA.
- There is a pressing need to improve the rate at which TIA patients receive appropriate antiplatelet medication upon discharge.
- Adherence to evidence-based antiplatelet strategies can significantly improve patient outcomes and reduce long-term mortality.
Abstract:
As many as 300,000 transient ischemic attacks (TIAs) occur in the United States each year, accounting for 0.3% of all Emergency Department visits. An under-recognized and under-treated problem, TIA is associated with up to a 10% risk of subsequent stroke within 7 days and a 25% risk of death at 1 year. Antiplatelet therapy can result in significant reductions in secondary stroke risk. However, nearly 50% of patients with TIA leave the Emergency Department without any medication. This article discusses recent results from major antiplatelet clinical trials in stroke prevention and highlights the need for appropriate and timely initiation of antiplatelet treatment in patients with TIA.
Related Concept Videos
01:26Transient Ischemic Attack l: Introduction
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:15Ischemic Stroke l: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:27Peripheral Artery Disease III: Interprofessional Care